Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
70.50    0.00 (0.00%)
Bid:
70.00
Ask:
71.00
Spread: 1.00 (1.429%)
Market Cap: £320.85m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Re Agreement

7 Jan 2008 10:50

Avacta Group plc

Strategic Alliance

Broader service offering augments market position

Avacta Group plc ("Avacta"), which provides novel detection and analysis technology for the pharmaceutical, defence & security and clinical diagnostics markets, announces an agreement with Agenda 1 Analytical Services Ltd ("Agenda 1").

Agenda 1 provides a wide range of analytical techniques and services from bespoke laboratories located close to Avacta in Bradford, UK. Agenda 1 provides a complementary service offering to Avacta by focusing on small molecule therapeutics, whereas Avacta's strength is in the provision of expert analysis to companies developing large molecule biopharmaceuticals. Consequently, the agreement provides an immediate synergy allowing Avacta to offer an enhanced analytical service to a much wider base of pharmaceutical companies along with access to expertise, resources and technology not available in-house.

The Directors of Avacta believe that this enhanced product offering will enable accelerated growth of the analytical services business because it affords Avacta the ability to offer a greater range of the services required by the pharmaceutical industry. There will be no consideration payable by Avacta for this sharing of services.

Professor Alastair Smith, Chief Executive Officer, Commented:

"Avacta Analytical Limited, Avacta's technical services subsidiary, has made very good progress in its provision of analytical services to the biopharmaceutical sector but we are aware that some potential clients require an even broader range of services than we have been able to offer to date. Today's agreement allows us to extend our services and cover a greater range of the pharmaceutical industry's requirements and my expectation is that this will lead to more rapid growth in the services business of the Group."

7 January 2008Enquiries:Avacta Group plc Tel: 0870 835 4367 Russell Hodgetts Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk WH Ireland Ltd (Nominated Adviser) Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Ltd Tel: 020 7562 4700 Michael Brennan/Henry Turcan Notes to Editors:About Avacta

Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address needs in the pharmaceutical, defence and clinical diagnostics markets. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High value solutions in defence and clinical diagnostics are also being provided by Avacta's development programmes.

A successful and growing part of the Avacta business model is its technical services arm, Avacta Analytical Ltd which is focused on providing leading edge contract research to the biopharmaceutical and healthcare/personal-care materials sectors. Avacta listed on AIM in August 2006 through the reverse takeover of Readybuy plc which changed its name to Avacta Group plc.

About Agenda 1

Agenda 1 grew from the analytical laboratories of Nektar Therapeutics (UK) Ltd - (a.k.a. Bradford Particle Design Ltd). The team was formed to utilise their experience as a development group supporting both new technologies and new pharmaceutical products working from early stage project initiation up to and including enabling the release of material for clinical trials.

Agenda 1's client base ranges from major pharmaceutical companies through to virtual companies, and emerging and growing Bio-Pharma businesses. Agenda 1 has developed a number of flexible approaches to help clients access their lab facilities. These include the option to place contract staff into the laboratories via a unique structure with Synergy Outsourcing, a company specialising in scientific personnel. Agenda 1 has also recently launched an innovative "Lab Time-Share" approach, which saw the company awarded the prestigious Royal Society of Chemistry "SME of the month" award for July 2007.

AVACTA GROUP PLC
Date   Source Headline
15th Jun 20204:36 pmRNSPrice Monitoring Extension
15th Jun 20202:05 pmRNSSecond Price Monitoring Extn
15th Jun 20202:00 pmRNSPrice Monitoring Extension
15th Jun 202011:05 amRNSSecond Price Monitoring Extn
15th Jun 202011:00 amRNSPrice Monitoring Extension
12th Jun 20207:00 amRNSHolding(s) in Company
10th Jun 20206:35 pmRNSHolding(s) in Company
9th Jun 20207:01 amRNSInvestor Presentation
9th Jun 20207:00 amRNSUpdate on COVID-19 Test Development with Adeptrix
8th Jun 20204:15 pmRNSPosting of Circular and Notice of General Meeting
4th Jun 20205:16 pmRNSDirector/PDMR Shareholding
4th Jun 20205:15 pmRNSResult of Fundraising
4th Jun 202012:30 pmRNSIncrease in Fundraising
4th Jun 202011:05 amRNSSecond Price Monitoring Extn
4th Jun 202011:00 amRNSPrice Monitoring Extension
4th Jun 20209:05 amRNSSecond Price Monitoring Extn
4th Jun 20209:00 amRNSPrice Monitoring Extension
4th Jun 20207:01 amRNSPrimaryBid.com Offers
4th Jun 20207:00 amRNSProposed Fundraising to raise up to £45 million
28th May 20207:00 amRNSPosting of Annual Report and Notice of AGM
26th May 202011:05 amRNSSecond Price Monitoring Extn
26th May 202011:00 amRNSPrice Monitoring Extension
26th May 20208:06 amRNSIssue of Equity
21st May 20202:05 pmRNSSecond Price Monitoring Extn
21st May 20202:00 pmRNSPrice Monitoring Extension
20th May 20207:00 amRNSDistribution Agreement for COVID-19 Antigen Test
15th May 20204:41 pmRNSSecond Price Monitoring Extn
15th May 20204:35 pmRNSPrice Monitoring Extension
15th May 20202:06 pmRNSSecond Price Monitoring Extn
15th May 20202:00 pmRNSPrice Monitoring Extension
15th May 202011:06 amRNSSecond Price Monitoring Extn
15th May 202011:00 amRNSPrice Monitoring Extension
15th May 20209:30 amRNSIssue of Equity
15th May 20207:00 amRNSSARS-COV-2 Neutralising Affimers
11th May 20207:00 amRNSAvacta Ships SARS-COV-2 Affimer Reagents
6th May 20207:00 amRNSResults for the period ending 31 December 2019
5th May 20206:15 pmRNSHolding(s) in Company
4th May 20204:41 pmRNSSecond Price Monitoring Extn
4th May 20204:36 pmRNSPrice Monitoring Extension
1st May 20207:00 amRNSCOVID-19 Antigen Test Collaboration with Adeptrix
27th Apr 20205:30 pmRNSHolding(s) in Company
27th Apr 20205:00 pmRNSHolding(s) in Company
24th Apr 20206:00 pmRNSHolding(s) in Company
24th Apr 20204:41 pmRNSSecond Price Monitoring Extn
24th Apr 20204:36 pmRNSPrice Monitoring Extension
24th Apr 20202:05 pmRNSSecond Price Monitoring Extn
24th Apr 20202:00 pmRNSPrice Monitoring Extension
23rd Apr 20204:40 pmRNSSecond Price Monitoring Extn
23rd Apr 20204:35 pmRNSPrice Monitoring Extension
23rd Apr 202010:18 amRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.